Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire and the Role of Dermatologists: A Report from the GRAPPA 2009 Annual Meeting: Table 1.

2011 ◽  
Vol 38 (3) ◽  
pp. 548-550 ◽  
Author(s):  
PATRICK DOMINGUEZ ◽  
M. ELAINE HUSNI ◽  
AMIT GARG ◽  
ABRAR A. QURESHI
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Physical Disability ◽  
Inflammatory Arthritis ◽  
Critical Role ◽  
Diagnosis And Treatment ◽  
Major Focus ◽  
Delay In Diagnosis ◽  
Erosive Arthropathy

Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis, often with a variable course that ranges from slowly progressive to rapidly destructive. Delay in diagnosis and treatment may lead to an irreversible erosive arthropathy, leading further to physical disability and deformity. The Psoriatic Arthritis Screening and Evaluation (PASE) tool was developed and validated to help dermatologists screen more effectively for PsA; recently, it has been undergoing further validation. An update on the continuing experience with the PASE questionnaire, along with a discussion of why dermatologists have a critical role in screening for PsA, was a major focus of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting at Stockholm, Sweden, in June 2009.

Cardiovascular Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting

2013 ◽  
Vol 40 (8) ◽  
pp. 1434-1437 ◽  
Author(s):  
April W. Armstrong ◽  
Joel M. Gelfand ◽  
Wolf-Henning Boehncke ◽  
Ehrin J. Armstrong
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Tumor Necrosis ◽  
Panel Discussion ◽  
Future Research ◽  
Research Directions ◽  
Cardiovascular Comorbidities ◽  
Future Research Directions ◽  
Necrosis Factor

At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Stockholm, Sweden, several GRAPPA members led a panel discussion on cardiovascular (CV) comorbidities of psoriasis and psoriatic arthritis (PsA). The panelists discussed the role of insulin resistance in the pathophysiology of psoriasis, the possible effect of tumor necrosis factor inhibitors on CV comorbidities, and the effect of 12/23 monoclonal antibodies on CV outcomes. The panelists also addressed how lessons from CV comorbidity research could be applied to other areas of comorbidity research in psoriasis and PsA and identified future research directions in this area.

Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2012 Annual Meeting

2013 ◽  
Vol 40 (8) ◽  
pp. 1442-1445 ◽  
Author(s):  
Philip J. Mease ◽  
Amit Garg ◽  
Dafna D. Gladman ◽  
Philip S. Helliwell
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Inflammatory Disease ◽  
Inflammatory Arthritis ◽  
Nominal Group Technique ◽  
Nominal Group ◽  
Clinical Criteria ◽  
Expert Clinician ◽  
Primary Care Clinicians ◽  
Definition Of

Dermatologist and primary care clinicians are in an ideal position to identify the emergence of psoriatic arthritis (PsA) in patients with psoriasis. Yet these clinicians are not well trained to distinguish inflammatory musculoskeletal disease from other more common problems such as osteoarthritis, traumatic or degenerative tendonitis and back pain, or fibromyalgia. A simple set of clinical criteria to identify inflammatory disease would aid recognition of PsA. At its 2012 annual meeting, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) discussed development of evidence-based, practical, and reliable definitions of inflammatory arthritis, enthesitis, dactylitis, and spondylitis. This project will be a sequential process of expert clinician nominal-group technique, patient surveys and focus groups, and Delphi exercises to identify core features of inflammatory disease, testing these in a small group of patients with and without inflammatory disease, and finally validating these criteria in larger groups of patients.

The Need to Define Musculoskeletal Inflammation: A Report from the GRAPPA 2010 Annual Meeting

2012 ◽  
Vol 39 (2) ◽  
pp. 413-414 ◽  
Author(s):  
AMIT GARG ◽  
DAFNA D. GLADMAN ◽  
PHILIP J. MEASE
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Inflammatory Arthritis ◽  
Disease Classification ◽  
Group Discussions ◽  
Diagnostic Measure ◽  
Breakout Group

Psoriatic arthritis (PsA) is a form of spondyloarthritis, a group of conditions that share a spectrum of components including arthritis, enthesitis, dactylitis, and spine inflammation. In PsA, however, the unpredictable, heterogeneous, and often insidious involvement of joints or juxtaarticular tendons and ligaments can sometimes make clinical recognition of the disease a challenge. Underrecognition of PsA may be due to the absence of a single sensitive and specific diagnostic measure. Although the ClASsification of Psoriatic ARthritis (CASPAR) criteria introduced in 2006 have improved disease classification, they are designed to be applied to cases already diagnosed with inflammatory arthritis. Therefore, in order for these criteria to be applied, the clinician is required to recognize the presence of inflammatory arthritis, enthesitis, or spondylitis. At the 2010 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), the need to define inflammatory arthritis, enthesitis, dactylitis, and spondylitis, especially for nonrheumatologists, was discussed. Conclusions from breakout group discussions are summarized.

Treatments for Psoriatic Arthritis, a Guide for Patients Written by Fellow Patients: A Report from the GRAPPA 2016 Annual Meeting

2017 ◽  
Vol 44 (5) ◽  
pp. 686-687 ◽  
Author(s):  
Denis O’Sullivan ◽  
Ingrid Steinkoenig ◽  
Mel Brooke
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Treatment Recommendations ◽  
Diagnosis And Treatment ◽  
Treatment Needs ◽  
Potential Patient

In 2016, members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published their updated Treatment Recommendations for Psoriatic Arthritis. This paper describes how a patient-oriented guide to those treatment recommendations was developed by GRAPPA’s patient research partners (PRP). We describe how the PRP developed a process for creating and implementing the guide. We also describe how we evaluated the diversity of the guide’s potential patient audience, i.e., where each individual was in their diagnosis and treatment needs, and how we made the patient guide attractive, readable, and available to as broad a patient audience as possible.

Distinguishing Inflammatory from Noninflammatory Arthritis, Enthesitis, and Dactylitis in Psoriatic Arthritis: A Report from the GRAPPA 2010 Annual Meeting: Table 1.

2012 ◽  
Vol 39 (2) ◽  
pp. 415-417 ◽  
Author(s):  
PHILIP J. MEASE
Keyword(s):  
Primary Care ◽  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Inflammatory Arthritis ◽  
Primary Care Providers ◽  
Musculoskeletal Disease ◽  
Care Providers ◽  
Key Variables

The most widely applied criteria for classifying psoriatic arthritis (PsA) are the CASPAR (ClASsification of Psoriatic ARthritis) criteria. A patient who fulfills the CASPAR criteria must have evidence of inflammatory arthritis, enthesitis, or spondylitis, and may have an inflammatory musculoskeletal component, dactylitis. Although the criteria were developed by rheumatologists, not all patients with PsA are seen by rheumatologists. Thus, it is important for clinicians such as dermatologists, primary care providers, physiatrists, and orthopedists, and patients themselves, to be able to recognize the presence of inflammatory musculoskeletal disease and distinguish it from degenerative or traumatic musculoskeletal disease. At their 2010 annual meeting, members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) discussed the steps they are taking to define the key variables that must be present to distinguish inflammatory arthritis, enthesitis, and dactylitis from degenerative, traumatic, mechanical, or infectious forms of these conditions.

Immunopathogenesis of psoriatic arthritis: Recent advances

Open Medicine ◽  
2008 ◽  
Vol 3 (3) ◽  
pp. 245-253
Author(s):  
Panayiotis Stavropoulos ◽  
Andreas Goules ◽  
Georgia Avgerinou ◽  
Andreas Katsambas
Keyword(s):  
Immune System ◽  
Psoriatic Arthritis ◽  
Inflammatory Response ◽  
Adhesion Molecules ◽  
Proinflammatory Cytokines ◽  
Inflammatory Arthritis ◽  
Angiogenic Factors ◽  
Chronic Inflammatory Arthritis ◽  
Immunologic Factors

AbstractPsoriatic Arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis. The pathophysiology of PsA includes genetic, environmental and immunologic factors. Recent studies revealed the dynamic role of the immune system in the pathogenesis of the disease. Adhesion molecules, proinflammatory cytokines, angiogenic factors and metalloproteinases appear to orchestrate the inflammatory response in PsA. This article summarizes the current immunologic findings and suggests future therapeutic and researching approaches in the field of PsA.

On Defining Musculoskeletal Inflammation: A Report from the GRAPPA 2011 Annual Meeting

2012 ◽  
Vol 39 (11) ◽  
pp. 2214-2215 ◽  
Author(s):  
AMIT GARG ◽  
DAFNA D. GLADMAN ◽  
PHILIP J. MEASE
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Inflammatory Arthritis ◽  
Classification Criteria ◽  
Musculoskeletal Disease ◽  
Group Discussions ◽  
Diagnostic Measure ◽  
Breakout Group

At the 2011 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members discussed the need to develop a framework for defining inflammatory arthritis, enthesitis, dactylitis, and spondylitis, particularly as they relate to psoriatic arthritis (PsA). GRAPPA members first addressed this subject at their 2010 meeting, where the CASPAR (ClASsification of Psoriatic ARthritis) criteria were discussed. Although these are classification criteria, the CASPAR are also often applied as a diagnostic measure by clinicians screening for PsA, particularly its core criterion: recognizing the presence of inflammatory musculoskeletal disease. In breakout group discussions, GRAPPA members discussed the difficulties in recognizing overlapping or mimicking features that may result in underdiagnosing or misdiagnosing PsA.

Sign in / Sign up

Export Citation Format

Share Document